DMARDs & Immunosuppressives

FDA Approves Ustekinumab for Children with PsA

November 7, 2022 • By Michele B. Kaufman, PharmD, BCGP

TNF Inhibitors Associated with Neurological Adverse Events

November 7, 2022 • By Michele B. Kaufman, PharmD, BCGP

JAK Inhibitors: Are All Promises Fulfilled?

July 22, 2022 • By Samantha C. Shapiro, MD

Challenges in Reproductive Health in Rheumatic Disease

July 11, 2022 • By Keri Losavio & Julie Nusbaum, MD

Early Data on Novel MK2 Inhibitor to Treat Inflammatory Diseases Promising

June 9, 2022 • By Michele B. Kaufman, PharmD, BCGP

European Medicines Agency Committee Issues Positive Opinion for Secukinumab in Pediatric Arthritic Disease

June 2, 2022 • By Michele B. Kaufman, PharmD, BCGP

Is Hydroxychloroquine Safe During Pregnancy?

March 31, 2022 • By Arthritis & Rheumatology

Beyond Trial & Error: RheumMadness 2022 AI: TNFi Response Scouting Report

February 14, 2022 • By Cleveland Clinic Foundation Rheumatology Fellowship Program: Saja Almaaitah, MD; Shashank Cheemalavagu, MD; Rupal Shastri, MD; Perry Fuchs, MD; Melany Gonzalez Orta, MD; & James Vondenberg, DO

Clinical Insights into Axial Spondyloarthritis: Rheumatology Drugs at a Glance, Part 5

February 10, 2022 • By Mary Choy, PharmD, BCGP, FASHP

New Data Highlight Effectiveness of Guselkumab for Patients with PsA

February 2, 2022 • By Michele B. Kaufman, PharmD, BCGP